| Literature DB >> 35684380 |
Chun-Yang Zhang1,2, Chao-Ping Fu1,2, Xiong-Ya Li1,2, Xiao-Chang Lu1,2, Long-Ge Hu1,2, Ranjith Kumar Kankala1,2, Shi-Bin Wang1,2, Ai-Zheng Chen1,2.
Abstract
Three-dimensional (3D) bioprinting is one of the most promising additive manufacturing technologies for fabricating various biomimetic architectures of tissues and organs. In this context, the bioink, a critical element for biofabrication, is a mixture of biomaterials and living cells used in 3D printing to create cell-laden structures. Recently, decellularized extracellular matrix (dECM)-based bioinks derived from natural tissues have garnered enormous attention from researchers due to their unique and complex biochemical properties. This review initially presents the details of the natural ECM and its role in cell growth and metabolism. Further, we briefly emphasize the commonly used decellularization treatment procedures and subsequent evaluations for the quality control of the dECM. In addition, we summarize some of the common bioink preparation strategies, the 3D bioprinting approaches, and the applicability of 3D-printed dECM bioinks to tissue engineering. Finally, we present some of the challenges in this field and the prospects for future development.Entities:
Keywords: 3D bioprinting; bioink; decellularized extracellular matrix; tissue engineering
Mesh:
Substances:
Year: 2022 PMID: 35684380 PMCID: PMC9182049 DOI: 10.3390/molecules27113442
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.927
Figure 1Schematic illustration highlighting the various decellularized extracellular matrix (dECM) preparation methods, and the bioink preparation strategies and applications of 3D bioprinting dECM-based bioinks in tissue engineering.
Figure 2Representative illustration of extracellular matrix (ECM) compositional layout indicating cellular engagement with ECM biomolecules and primary components of general ECM space [28].
Overview of decellularized methods.
| Tissue or Organ Sources | Decellularized Method | Mode of Digestion | Ref. |
|---|---|---|---|
| Porcine lateral and medial menisci | Frozen for 5 min and thawed at 21 °C for 10 min 6 times; 0.25% trypsin for 8 h; 3% SDS for 72 h; 50 U/mL DNAse in PBS for 48 h | 0.1% peracetic acid | [ |
| Porcine cartilage tissue | Freeze–thaw cycles 3 times; 1% Triton X-100 for 1 d; immersed in 1% SDS for 24 h; 200 U/mL DNase I for 12 h | 0.5 M acetic acid with 30 mg of pepsin for 48 h | [ |
| Goat articular cartilage tissue | 0.1% EDTA and 3.5% PMSF for 24 h; 1% Triton X-100 in Tris-HCl (pH = 7.5) with a protease inhibitor cocktail for 24 h; 50 U/mL DNAse and 1 U/mL RNAse for 12 h | 1 mL of 0.1 M HCl containing 1 mg of pepsin for 48 h | [ |
| Human auricular cartilage | 4% SDS for 3 h; 1000 U/mL DNase for 3 h | - | [ |
| Porcine tendon tissues | 100% acetone for 30 min; 0.25% trypsin-EDTA; 2% SDS for 96 h | 3 mg mL−1 pepsin in 0.1 M HCl | [ |
| Porcine auricular cartilage | Immersed in 0.02% Tris/EDTA with protease inhibitor for 48 h; 1% Triton X-100; incubated with DNAse/RNAse (15 μg/mL) for 24 h; retreated with 0.02% Tris/EDTA solution for 48 h | - | [ |
| Porcine liver | 0.025% trypsin for 30 min 1% Triton solution for 24 h; 2% SDS for 36 h | Digested in 0.5 M acetic acid and pepsin solution for 96 h | [ |
| Rat liver | 1% Triton X-100 for 2 h; 0.1% SDS for 1 h; 750 U/mL DNAse and 25 U/mL RNAse for 30 min | Digested in 1 mg/mL of HCl (0.1 M) of pepsin for 72 h | [ |
| Porcine liver | 0.5% Triton X-100 for 9 h; 1% SDS for 3 h | - | [ |
| Rat liver | 1% Triton x-100 with 0.1% NH4OH (15 mL/min, 1 h; 20 mL/min, 2 h); sterile DI water (5 mL/min, 40 min; 15 mL/min, 15 min; 20 mL/min, 45 min); 0.1% peracetic acid (PAA) in 4% alcohol (5 mL/min, 40 min); submerged in PAA (30 min); sterile DI water (5 mL/min, overnight) | - | [ |
| Porcine, canine, human, rat liver | Exposed the liver tissue to trypsin/EGTA and Triton X-100 | Digested in pepsin solution | [ |
| Porcine liver | 0.1% SDS wash overnight | Digested at a 10 mg/mL dECM and 1 mg/mL pepsin at 0.01 M HCl for 48 h | [ |
| Porcine skin | 0.25% trypsin for 6 h; 70% ethanol for 10 h; 3% H2O2 for 15 min; 1% Triton X-100 in 0.26% EDTA/0.69% Tris for 6 h with a solution change for an additional 16 h; 0.1% peracetic acid/4% ethanol for 2 h | Digested in a 1 mg/mL pepsin solution in 0.01 N HCl for 48 h at 10 mg ECM/mL solution | [ |
| Porcine skin | 0.25% trypsin for 6 h; 1% Triton X-100 for 24 h; 10% isopropanol for 24 h; 30 U/mL DNase for 24 h; 0.1% peracetic acid in 4% ethanol for 2 h | Digested in papain solution (125 μg/mL) for 16 h | [ |
| Nile tilapia skin | 2.5 U/mL disperse for 3 h; 1% SDS for 6 h; 25 U/mL Pierce Universal Nuclease for 3 h; 1% SDS for 1 h | - | [ |
| Groin skin | Cycle freeze–thaw 3 times; 0.25% trypsin/EDTA for 2 h; processed with isopropanol overnight; treated with 1% Triton X-100 for 48 h | - | [ |
| Porcine peritoneum | Treated with a solution (pH 5.6) containing 2% SDS and 0.3% NaCl; ultrasonic treatment for 24 h; | - | [ |
| Porcine small intestinal submucosa | Treated with mechanical removal of the tunica mucosa, the tunica serosa, and the tunica muscularis externa; treated with peracetic acid to remove remaining cells, RNA, and DNA | - | [ |
| Porcine skin | 0.25 wt% trypsin and 1 mM EDTA for 6 h; 1 wt% TritonX-100 for 24 h; 30 U/mL DNase for 24 h | 0.5 M acetic acid solution containing 15 mg of pepsin per 100 mg dECM for 120 h | [ |
| Porcine lateral and medial menisci | Frozen in liquid nitrogen for 5 min and then thawed at 21 °C for 10 min repeated 6 times; 0.25% ( | Lyophilized and pulverized into fine powder | [ |
| Rat heart | Perfused through the ascending aorta with 200 mL of PBS containing heparin (20 U/mL) and 10 mM adenosine followed by 0.1% SDS, deionized water, 1% Triton X-100, 100 U/mL penicillin-G (Gibco), 100 U/mL streptomycin, and 100 U/mL amphotericin B | - | [ |
| Porcine heart | 0.1% SDS containing 7 mmol/L EDTA for 24 h, washed with 70% ethanol | 2.0 mL of 6.0 N HCl for 24 h | [ |
| porcine aortic valves and pericardia | 5 mM Tris buffer with 1% Triton X-100 for 24 h; HBSS medium supplemented with 100 mg/L DNase, 20 mg/L RNase and 100 mg/L trypsin for 90 min; new 5 mM Tris buffer with 1% Triton X-100 for 24 h | - | [ |
| Porcine myocardium | PBS solution with 1.0% Triton X-100 for 72 h; 20 mg/mL ribonuclease A and 0.2 mg/mL deoxyribonuclease for 48 h | 0.05% collagenase, type IV, 0.5 mg/mL pancreatin, 1 mg/mL BSA solution | [ |
| Zebrafish ventricular wall | Repeated freeze–thaw cycles, red blood cells, and DNA/RNA are removed by the erythrolysis buffer and deoxyribonuclease/ribonuclease | Mechanically ground into fine powders in liquid nitrogen | [ |
| Porcine vena cava | 0.1% SDS for 16 h; 40 U/mL DNase for 2 h | - | [ |
| Saphenous vein | 0.25% trypsin with 0.02% EDTA for 5 min; 10 mmol/L Tris, 5 mmol/L EDTA for 72 h; frozen at −80 °C for 2 h and thawing at 37 °C for 30 min | 50 mL 10 mM ethylenediaminetetraactic acid | [ |
| Wistar rat kidney | Perfusated by 1% SDS | 5 mL of papain solution for 24 h | [ |
| Porcine kidney | Repetitive cycle of: perfused with 0.5 M NaCl solution for 30 min; 0.5% SDS solution for 30 min; deionized (DI) water for 30 min | Lyophilize and mechanically ground into fine powders | [ |
| Rat kidney | Perfused with 1% SDS for 4 h or 1% SLES for 6 h | - | [ |
| Rat kidney | perfused with 1% SDS for 3 h and 1% Triton X-100 for 16 h | - | [ |
| Rabbit kidney | Perfused with 1% SDS for 90 h, 2% Triton X-100 for 12 h | - | [ |
| Rat kidney | Perfused with 1% SDS for 48 h, 0.2 mg/mL deoxyribonuclease I and 10 mM MgCl2 for 16 h | - | [ |
| Rhesus monkey kidney | Perfused with 1% SDS and 1% Triton X-100 | - | [ |
| Porcine kidney | Perfused with 1% SDS for 28 h, 1% Triton X-100 for 2 h | Incubation with papain extraction reagent for 3 h | [ |
| Porcine skin | 0.25% trypsin for 6 h; 0.1% SDS in 0.26% EDTA with 0.69% Tris for 6 h; 1% Triton X-100 in 0.26% EDTA with 0.69% Tris for 12 h | Lyophilized and dried for 72 h | [ |
Figure 3Strategies for preparing decellularized bioinks. (A) Illustration of cdECMMA bioink formulation containing cells and three-dimensional (3D) bioprinting process using cell-laden cdECMMA bioink: (i) Preparation of cdECMMA; and (ii) schematic diagram of preparation mechanism of cdECMMA [23]; (B) Schematic representation of the preparation of dECM powder–based bioink (i) and its application to bioprinting (ii) [25].
Figure 4Schematic diagram of three representative 3D bioprinting technology devices: (A) extrusion bioprinting; (B) inject bioprinting; (C) DLP bioprinting.
Figure 53D bioprinting of biocompatible and functional meniscus constructs using meniscus-derived bioink: (i) decellularization process of meniscus; (ii) rheological properties of me-dECM bioink and COL bioink; (iii) CAD-based 3D bioprinting of diverse meniscus constructs of rabbit, beagle, and human models [138].
Figure 6A typical example of liver-derived dECM bioink for 3D printing application: (i) digital image of fresh porcine liver/liver dECM/lyophilized liver dECM; (ii) schematic of DLP-based 3D printer; (iii) designed liver microtissue model and DLP printing results [68].
Figure 7Two examples of skin-derived dECM bioinks for 3D printing applications. (A) Skin-derived bioink formulation and its properties analysis: (i) S-dECM bioink preparation process; (ii) quantitative analyses of dECM bioink, including collagen, GAGs, elastin, hyaluronic acid, and DNA; (iii) sol-gel transition of dECM bioink; and (iv) printability test of dECM bioink [142]; (B) Structure of the 3D-printed construct using skin bioink and gene expression: (i) cell-laden 3D scaffold; and (ii) changes in gene expression in the 3D-printed cell-laden construct [80].
Figure 8Two examples of cardiac-derived dECM bioinks for 3D printing applications. (A) Schematic illustration of a new cardiac-derived dECM bioink for 3D printing: (i) schematic illustration of a two-step cross-linking mechanism that applies concurrent cross-linking of vitamin B2-induced covalent cross-linking and thermal cross-linking; (ii) 3D printing and cross-linking; and (iii) digital image of the scaffold [144]; (B) Schematic depicting the stages starting with the preparation of the hdECM bioink to fabrication of the cell-laden EHT: (i) development of the hdECM bioink; and (ii) fabrication of the cardiomyocyte-laden EHT using a 3D bioprinter [145].
Figure 9Schematic of research strategy: (i) schematic diagram of manufacturing coaxial vascular device and materials; (ii) schematic diagram of the coaxial blood vessel [146].
Figure 10Preparation of KdECM and KdECMMA-based bioink formulations: changes in gene expression in the 3D-printed cell-laden construct: (i) gross images of the decellularization process: (a) normal kidney, (b) SDS treatment for 36 h, (c) Triton X-100 treatment for 24 h, and (d) washing in saline for 72 h; (ii) schematic illustration of a photo-cross-linkable kidney-specific ECM hydrogel; (iii) photography of KdECMMA before and after UV cross-linking; (iv) printing code and gross images of the printed KdECMMA-based constructs [147].